Skip to main content

Advertisement

Table 1 Demographic characteristics of the study participants

From: Immune responses in the treatment of drug-sensitive pulmonary tuberculosis with phenylbutyrate and vitamin D3 as host directed therapy

Characteristics Placebo (n = 32) PBA (n = 32) vitD3 (n = 31) PBA + vitD3 (n = 32)
Age, years 27.38 ± 8.65 27.72 ± 7.25 25.42 ± 8.15 27.16 ± 8.38
Males 20 (62.50%) 22 (25.90%) 21 (67.70%) 22 (68.80%)
History of contacts 10 (31.30%) 11 (34.40%) 6 (19.40%) 8 (25.00%)
BCG given 22 (68.8%) 19 (59.4%) 26 (83.90%) 23 (71.90%)
Weight, kg 44.75 ± 8.20 45.74 ± 8.91 42.91 ± 8.70 44.00 ± 7.89
Duration of illness, days 48.91 ± 25.42 50.63 ± 21.80 58.39 ± 26.81 52.47 ± 27.58
Vitamin D status
 Deficient, < 30 nmol/L 18 (56%) 23 (71%) 21 (67%) 16 (50%)
 Insufficient, 30–50 nmol/L 10 (31.30%) 6 (18.8%) 5 (16.10%) 12 (37.50%)
 Sufficient, > 50 nmol/L 4 (12.50%) 3 (9.4%) 5 (16.10%) 4 (12.50%)
Baseline clinical score (25) 6.47 ± 0.86 6.45 ± 1.09 6.27 ± 1.01 6.39 ± 0.96
Baseline sputum smear
 < 3 acid-fast bacilli 17 (43.10%) 17 (43.10%) 16 (51.60%) 18 (56.20%)
 > 3 acid-fast bacilli 15 (46.90%) 15 (46.90%) 15 (48.40%) 14 (43.80%)
  1. Data is presented as mean ± standard deviation or number with percentage in parentheses
  2. Abbreviations: BCG Bacillus Calmette–Guérin